18 results on '"Starmans-Kool, Mirian"'
Search Results
2. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial
- Author
-
Cope, Andrew P, Jasenecova, Marianna, Vasconcelos, Joana C, Filer, Andrew, Raza, Karim, Qureshi, Sumera, D'Agostino, Maria Antonietta, Mcinnes, Iain B, Isaacs, John D, Pratt, Arthur G, Fisher, Benjamin A, Buckley, Christopher D, Emery, Paul, Ho, Pauline, Buch, Maya H, Ciurtin, Coziana, van Schaardenburg, Dirkjan, Huizinga, Thoma, Toes, René, Georgiou, Evangelo, Kelly, Joanna, Murphy, Caroline, Prevost, A Toby, Norton, Sam, Lempp, Heidi, Opena, Maria, Subesinghe, Sujith, Garrood, Toby, Menon, Bina, Ng, Nora, Douglas, Karen, Koutsianas, Christo, Cooles, Faye, Falahee, Marie, Echavez-Naguicnic, Irene, Bharadwaj, Anurag, Villaruel, Michael, Pande, Ira, Collins, David, Pegler, Suzannah, Raizada, Sabrina, Siebert, Stefan, Fragoulis, George, Guinto, Jesusa, Galloway, Jame, Rutherford, Andrew, Barnes, Theresa, Jeffrey, Helen, Patel, Yusuf, Batley, Michael, O'Reilly, Brendan, Venkatachalam, Srivinisan, Sheeran, Thoma, Gorman, Claire, Reynolds, Piero, Khan, Asad, Gullick, Nicola, Banerjee, Siwalik, Mankia, Kulveer, Jordan, Deepak, Rowlands, Jane, Starmans-Kool, Mirian, Taylor, Jame, Nandi, Pradip, Sahbudin, Ilfita, Maybury, Mark, Hider, Samantha, Barcroft, Ann, Mcnally, Jeremy, Kitchen, Jo, Nisar, Muhammad, Quick, Vanessa, D'Agostino, Maria Antonietta (ORCID:0000-0002-5347-0060), Cope, Andrew P, Jasenecova, Marianna, Vasconcelos, Joana C, Filer, Andrew, Raza, Karim, Qureshi, Sumera, D'Agostino, Maria Antonietta, Mcinnes, Iain B, Isaacs, John D, Pratt, Arthur G, Fisher, Benjamin A, Buckley, Christopher D, Emery, Paul, Ho, Pauline, Buch, Maya H, Ciurtin, Coziana, van Schaardenburg, Dirkjan, Huizinga, Thoma, Toes, René, Georgiou, Evangelo, Kelly, Joanna, Murphy, Caroline, Prevost, A Toby, Norton, Sam, Lempp, Heidi, Opena, Maria, Subesinghe, Sujith, Garrood, Toby, Menon, Bina, Ng, Nora, Douglas, Karen, Koutsianas, Christo, Cooles, Faye, Falahee, Marie, Echavez-Naguicnic, Irene, Bharadwaj, Anurag, Villaruel, Michael, Pande, Ira, Collins, David, Pegler, Suzannah, Raizada, Sabrina, Siebert, Stefan, Fragoulis, George, Guinto, Jesusa, Galloway, Jame, Rutherford, Andrew, Barnes, Theresa, Jeffrey, Helen, Patel, Yusuf, Batley, Michael, O'Reilly, Brendan, Venkatachalam, Srivinisan, Sheeran, Thoma, Gorman, Claire, Reynolds, Piero, Khan, Asad, Gullick, Nicola, Banerjee, Siwalik, Mankia, Kulveer, Jordan, Deepak, Rowlands, Jane, Starmans-Kool, Mirian, Taylor, Jame, Nandi, Pradip, Sahbudin, Ilfita, Maybury, Mark, Hider, Samantha, Barcroft, Ann, Mcnally, Jeremy, Kitchen, Jo, Nisar, Muhammad, Quick, Vanessa, and D'Agostino, Maria Antonietta (ORCID:0000-0002-5347-0060)
- Abstract
Background: Individuals with serum antibodies to citrullinated protein antigens (ACPA), rheumatoid factor, and symptoms, such as inflammatory joint pain, are at high risk of developing rheumatoid arthritis. In the arthritis prevention in the pre-clinical phase of rheumatoid arthritis with abatacept (APIPPRA) trial, we aimed to evaluate the feasibility, efficacy, and acceptability of treating high risk individuals with the T-cell co-stimulation modulator abatacept. Methods: The APIPPRA study was a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial done in 28 hospital-based early arthritis clinics in the UK and three in the Netherlands. Participants (aged ≥18 years) at risk of rheumatoid arthritis positive for ACPA and rheumatoid factor with inflammatory joint pain were recruited. Exclusion criteria included previous episodes of clinical synovitis and previous use of corticosteroids or disease-modifying antirheumatic drugs. Participants were randomly assigned (1:1) using a computer-generated permuted block randomisation (block sizes of 2 and 4) stratified by sex, smoking, and country, to 125 mg abatacept subcutaneous injections weekly or placebo for 12 months, and then followed up for 12 months. Masking was achieved by providing four kits (identical in appearance and packaging) with pre-filled syringes with coded labels of abatacept or placebo every 3 months. The primary endpoint was the time to development of clinical synovitis in three or more joints or rheumatoid arthritis according to American College of Rheumatology and European Alliance of Associations for Rheumatology 2010 criteria, whichever was met first. Synovitis was confirmed by ultrasonography. Follow-up was completed on Jan 13, 2021. All participants meeting the intention-to-treat principle were included in the analysis. This trial was registered with EudraCT (2013-003413-18). Findings: Between Dec 22, 2014, and Jan 14, 2019, 280 individuals were evaluated for el
- Published
- 2024
3. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial
- Author
-
Cope, Andrew P, primary, Jasenecova, Marianna, additional, Vasconcelos, Joana C, additional, Filer, Andrew, additional, Raza, Karim, additional, Qureshi, Sumera, additional, D'Agostino, Maria Antonietta, additional, McInnes, Iain B, additional, Isaacs, John D, additional, Pratt, Arthur G, additional, Fisher, Benjamin A, additional, Buckley, Christopher D, additional, Emery, Paul, additional, Ho, Pauline, additional, Buch, Maya H, additional, Ciurtin, Coziana, additional, van Schaardenburg, Dirkjan, additional, Huizinga, Thomas, additional, Toes, René, additional, Georgiou, Evangelos, additional, Kelly, Joanna, additional, Murphy, Caroline, additional, Prevost, A Toby, additional, Norton, Sam, additional, Lempp, Heidi, additional, Opena, Maria, additional, Subesinghe, Sujith, additional, Garrood, Toby, additional, Menon, Bina, additional, Ng, Nora, additional, Douglas, Karen, additional, Koutsianas, Christos, additional, Cooles, Faye, additional, Falahee, Marie, additional, Echavez-Naguicnic, Irene, additional, Bharadwaj, Anurag, additional, Villaruel, Michael, additional, Pande, Ira, additional, Collins, David, additional, Pegler, Suzannah, additional, Raizada, Sabrina, additional, Siebert, Stefan, additional, Fragoulis, George, additional, Guinto, Jesusa, additional, Galloway, James, additional, Rutherford, Andrew, additional, Barnes, Theresa, additional, Jeffrey, Helen, additional, Patel, Yusuf, additional, Batley, Michael, additional, O'Reilly, Brendan, additional, Venkatachalam, Srivinisan, additional, Sheeran, Thomas, additional, Gorman, Claire, additional, Reynolds, Piero, additional, Khan, Asad, additional, Gullick, Nicola, additional, Banerjee, Siwalik, additional, Mankia, Kulveer, additional, Jordan, Deepak, additional, Rowlands, Jane, additional, Starmans-Kool, Mirian, additional, Taylor, James, additional, Nandi, Pradip, additional, Sahbudin, Ilfita, additional, Maybury, Mark, additional, Hider, Samantha, additional, Barcroft, Ann, additional, McNally, Jeremy, additional, Kitchen, Jo, additional, Nisar, Muhammad, additional, and Quick, Vanessa, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Neuropathic‐like pain symptoms in inflammatory hand osteoarthritis lower quality of life and may not decrease under prednisolone treatment
- Author
-
van der Meulen, Coen, primary, van de Stadt, Lotte A., additional, Kroon, Féline P.B., additional, Kortekaas, Marion C., additional, Boonen, Annelies E.R.C.H., additional, Böhringer, Stefan, additional, Niesters, Marieke, additional, Reijnierse, Monique, additional, Rosendaal, Frits R., additional, Riyazi, Naghmeh, additional, Starmans‐Kool, Mirian, additional, Turkstra, Franktien, additional, van Zeben, Jendé, additional, Allaart, Cornelia F., additional, and Kloppenburg, Margreet, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial
- Author
-
Molto, Anna, López-Medina, Clementina, Van den Bosch, Filip E, Boonen, Annelies, Webers, Casper, Dernis, Emanuelle, van Gaalen, Floris A, Soubrier, Martin, Claudepierre, Pascal, Baillet, Athan, Starmans-Kool, Mirian, Spoorenberg, Anneke, Jacques, Peggy, Carron, Philippe, Joos, Rik, Lenaerts, Jan, Gossec, Laure, Pouplin, Sophie, Ruyssen-Witrand, Adeline, Sparsa, Laetitia, van Tubergen, Astrid, van der Heijde, Désirée, Dougados, Maxime, Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Equipe 4 : ECaMO - Épidémiologie clinique appliquée aux maladies rhumatismales et musculo-squelettiques (CRESS - U1153), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Ghent University Hospital, Maastricht University [Maastricht], Centre Hospitalier Le Mans (CH Le Mans), Leiden University Medical Center (LUMC), CHU Clermont-Ferrand, Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Henri Mondor, University Medical Center Groningen [Groningen] (UMCG), VIB-UGent Center for Inflammation Research [Gand, Belgique] (IRC), VIB [Belgium], Ziekenhuis Netwerk Antwerpen (ZNA), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de Rhumatologie [CHU Pitié Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Maastricht University Medical Centre (MUMC), Hôpital Cochin [AP-HP], Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation, Interne Geneeskunde, MUMC+: MA Reumatologie (9), MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
[SDV]Life Sciences [q-bio] ,Immunology ,Genetics and Molecular Biology ,IMPROVEMENT ,RECOMMENDATIONS ,Rheumatology ,Spondyloarthritis ,Spondylarthritis ,therapeutics ,Humans ,Immunology and Allergy ,DISEASE-ACTIVITY SCORE ,CRITERIA ,Spondylitis, Ankylosing ,ASAS ,Biology and Life Sciences ,healthcare ,ANKYLOSING-SPONDYLITIS ,spondylitis ,outcome and process assessment ,ABILITY ,RHEUMATOID-ARTHRITIS ,ankylosing ,PSORIATIC-ARTHRITIS ,General Biochemistry ,ADALIMUMAB - Abstract
Objectives To compare the benefits of a tight-control/treat-to-target strategy (TC/T2T) in axial spondyloarthritis (axSpA) with those of usual care (UC). Methods Pragmatic, prospective, cluster-randomised, controlled, open, 1-year trial (NCT03043846). 18 centres were randomised (1:1). Patients met Axial Spondylo Arthritis International Society (ASAS) criteria for axSpA, had an Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥2.1, received non-optimal treatment by non-steroidal anti-inflammatory drugs and were biologic-naive. Interventions (1) TC/T2T: visits every 4 weeks and prespecified strategy based on treatment intensification until achieving target (ie, ASDAS
- Published
- 2021
6. Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial
- Author
-
van Boheemen, Laurette, primary, Turk, Samina, additional, Beers-Tas, Marian van, additional, Bos, Wouter, additional, Marsman, Diane, additional, Griep, Ed N, additional, Starmans-Kool, Mirian, additional, Popa, Calin D, additional, van Sijl, Alper, additional, Boers, Maarten, additional, Nurmohamed, Michael T, additional, and van Schaardenburg, Dirkjan, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
- Author
-
Gerlag, Danielle M, primary, Safy, Mary, additional, Maijer, Karen I, additional, Tang, Man Wai, additional, Tas, Sander W, additional, Starmans-Kool, Mirian J F, additional, van Tubergen, Astrid, additional, Janssen, Matthijs, additional, de Hair, Maria, additional, Hansson, Monika, additional, de Vries, Niek, additional, Zwinderman, Aeilko H, additional, and Tak, Paul P, additional
- Published
- 2018
- Full Text
- View/download PDF
8. Clinical applications of arterial stiffness, Task Force III: recommendations for user procedures
- Author
-
Van Bortel, Luc M., Duprez, Daniel, Starmans-Kool, Mirian J., Safar, Michel E., Giannattasio, Christina, Cockcroft, John, Kaiser, Daniel R., and Thuillez, Christian
- Published
- 2002
- Full Text
- View/download PDF
9. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Randomized Multicenter Open-Label Controlled Trial
- Author
-
Moghadam, Marjan Ghiti, Vonkeman, Harald E., ten Klooster, Peter M., Tekstra, Janneke, van Schaardenburg, Dirkjan, Starmans-Kool, Mirian, Brouwer, Elisabeth, Bos, Reinhard, Lems, Willem F., Colin, Edgar M., Allaart, Cornelia F., Meek, Inger L., Landewe, Robert, Moens, Hein J. Bernelot, van Riel, Piet L. C. M., van de Laar, Mart A. F. J., Jansen, Tim L., Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), and Translational Immunology Groningen (TRIGR)
- Subjects
EULAR RECOMMENDATIONS ,2013 UPDATE ,INFLIXIMAB ,MODIFYING ANTIRHEUMATIC DRUGS ,ETANERCEPT ,DISCONTINUATION ,CRITERIA ,CONTROLLED-TRIAL ,THERAPY ,VALIDATION - Abstract
Objective. Tumor necrosis factor inhibitor (TNFi) biologic agents are an effective treatment for rheumatoid arthritis (RA). It is unclear whether patients whose disease is in remission or who have stable low disease activity need to continue use of TNFi or can stop this treatment. This study was undertaken to assess whether patients with established RA who are in remission or have stable low disease activity can effectively and safely stop their TNFi therapy. Methods. The study was designed as a pragmatic multicenter, open-label randomized controlled trial. Inclusion criteria were a diagnosis of RA according to the American College of Rheumatology 1987 classification criteria, as well as use of a TNFi for at least 1 year along with a stable dose of disease-modifying antirheumatic drugs and a Disease Activity Score in 28 joints (DAS28) of = 3.2 during the 12-month follow-up period and an increase in score of >= 0.6 compared to the baseline DAS28. Results. In total, 531 patients were allocated to the stop group and 286 to the TNFi continuation group. At 12 months, more patients had experienced a flare in the stop group (272 [51.2%] of 531) than in the continuation group (52 [18.2%] of 286; P Conclusion. Stopping TNFi treatment results in substantially more flares than does continuation of TNFi in patients with established RA in remission or with stable low disease activity.
- Published
- 2016
10. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open‐Label Randomized Controlled Trial
- Author
-
Ghiti Moghadam, Marjan, Vonkeman, Harald E., ten Klooster, Peter M., Tekstra, Janneke, van Schaardenburg, Dirkjan, Starmans-Kool, Mirian, Brouwer, Elisabeth, Bos, Reinhard, Lems, Willem F., Colin, Edgar M., Allaart, Cornelia F., Meek, Inger L., Landewé, Robert, Bernelot Moens, Hein J., van Riel, Piet L. C. M., van de Laar, Mart A. F. J., Jansen, Tim L., Faculty of Behavioural, Management and Social Sciences, Psychology, Health & Technology, Clinical Immunology and Rheumatology, and AII - Amsterdam institute for Infection and Immunity
- Subjects
IR-99684 ,METIS-316150 - Abstract
OBJECTIVE: Tumor necrosis factor inhibitor (TNFi) biologic agents are an effective treatment for rheumatoid arthritis (RA). It is unclear whether patients whose disease is in remission or who have stable low disease activity need to continue use of TNFi or can stop this treatment. This study was undertaken to assess whether patients with established RA who are in remission or have stable low disease activity can effectively and safely stop their TNFi therapy. METHODS: The study was designed as a pragmatic multicenter, open‐label randomized controlled trial. Inclusion criteria were a diagnosis of RA according to the American College of Rheumatology 1987 classification criteria, as well as use of a TNFi for at least 1 year along with a stable dose of disease‐modifying antirheumatic drugs and a Disease Activity Score in 28 joints (DAS28) of
- Published
- 2016
11. Schuurmans A. Farmacotherapeutische casuïstiek
- Author
-
Starmans-Kool, Mirian
- Published
- 2002
- Full Text
- View/download PDF
12. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study.
- Author
-
Gerlag, Danielle M., Safy, Mary, Maijer, Karen I., Man Wai Tang, Tas, Sander W., Starmans-Kool, Mirian J. F., van Tubergen, Astrid, Janssen, Matthijs, de Hair, Maria, Hansson, Monika, de Vries, Niek, Zwinderman, Aeilko H., and Tak, Paul P.
- Published
- 2019
- Full Text
- View/download PDF
13. High dietary salt intake increases carotid blood pressure and wave reflection in normotensive healthy young men
- Author
-
Starmans-Kool, Mirian J., primary, Stanton, Alice V., additional, Xu, Yun Y., additional, McG Thom, Simon A., additional, Parker, Kim H., additional, and Hughes, Alun D., additional
- Published
- 2011
- Full Text
- View/download PDF
14. Measurement of hemodynamics in human carotid artery using ultrasound and computational fluid dynamics
- Author
-
Starmans-Kool, Mirian J., primary, Stanton, Alice V., additional, Zhao, Shunzhi, additional, Xu, X. Yun, additional, Thom, Simon A. M., additional, and Hughes, Alun D., additional
- Published
- 2002
- Full Text
- View/download PDF
15. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial.
- Author
-
Molto A, López-Medina C, Van den Bosch FE, Boonen A, Webers C, Dernis E, van Gaalen FA, Soubrier M, Claudepierre P, Baillet A, Starmans-Kool M, Spoorenberg A, Jacques P, Carron P, Joos R, Lenaerts J, Gossec L, Pouplin S, Ruyssen-Witrand A, Sparsa L, van Tubergen A, van der Heijde D, and Dougados M
- Subjects
- Adult, Antirheumatic Agents economics, Biological Products economics, Cost-Benefit Analysis, Female, Humans, Male, Middle Aged, Quality-Adjusted Life Years, Spondylarthropathies economics, Spondylarthropathies physiopathology, Treatment Outcome, Antirheumatic Agents therapeutic use, Biological Products therapeutic use, Patient Care Planning, Spondylarthropathies drug therapy
- Abstract
Objectives: To compare the benefits of a tight-control/treat-to-target strategy (TC/T2T) in axial spondyloarthritis (axSpA) with those of usual care (UC)., Methods: Pragmatic, prospective, cluster-randomised, controlled, open, 1-year trial (NCT03043846). 18 centres were randomised (1:1). Patients met Axial Spondylo Arthritis International Society (ASAS) criteria for axSpA, had an Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥2.1, received non-optimal treatment by non-steroidal anti-inflammatory drugs and were biologic-naive., Interventions: (1) TC/T2T : visits every 4 weeks and prespecified strategy based on treatment intensification until achieving target (ie, ASDAS <2.1); (2) UC: visits every 12 weeks and treatment at the rheumatologist's discretion., Main Outcome: Percentage of patients with a ≥30% improvement on the ASAS-Health Index (ASAS-HI). Other efficacy outcomes and adverse events were recorded. A health economic evaluation was performed., Statistical Analysis: Two-level mixed models were used to estimate efficacy outcomes. Cost-effectiveness was assessed by the incremental cost per quality-adjusted life-year (QALY) gained for TC/T2T versus UC., Results: 160 patients were included (80/group). Mean (SD) age was 37.9 (11.0) years and disease duration was 3.7 (6.2) years; 51.2% were men. ASDAS at inclusion was 3.0 (0.7), and ASAS-HI was 8.6 (3.7). ASAS-HI improved by ≥30% in 47.3% of the TC/T2T arm and in 36.1% of those receiving UC (non-significant). All secondary efficacy outcomes were more frequent in the TC/T2T arm, although not all statistically significant. Safety was similar in both arms. From a societal perspective, TC/T2T resulted in an additional 0.04 QALY, and saved €472 compared with UC., Conclusion: TC/T2T was not significantly superior to UC for the primary outcome, while many secondary efficacy outcomes favoured it, had a similar safety profile and was favourable from a societal health economic perspective., Trial Registration Number: NCT03043846., Competing Interests: Competing interests: Dr van Tubergen reports grants and personal fees from Novartis, grants from Pfizer, grants from UCB, grants from Biogen, grants from AbbVie, outside the submitted work. Dr van der Heijde reports personal fees from AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eisai, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma, outside the submitted work; and Director of Imaging Rheumatology bv. Dr van Gaalen reports grants from Stichting vrienden van Sole Mio, grants from Stichting ASAS, grants and personal fees from Novartis, grants from UCB, personal fees from MSD, personal fees from AbbVie, personal fees from Bristol Myers Squibb, outside the submitted work. AB received a research grant to her department from AbbVie, consultation fees from Eli Lilly and Galapagos and a speakers fee from UCB, all paid to her department. Dr Van den Bosch reports personal fees from AbbVie, personal fees from Celgene, personal fees from Eli Lilly, personal fees from Galapagos, personal fees from Janssen, personal fees from Novartis, personal fees from Pfizer, personal fees from UCB, outside the submitted work. Dr Claudepierre reports personal fees from Roche Chugai, Novartis, Pfizer, MSD, grants from Roche Chugai, Novartis, Pfizer, UCB, MSD, AbbVie, Lilly, Celgene, Janssen, BMS, outside the submitted work. Dr Molto reports grants from UCB during the conduct of the study; personal fees from AbbVie, grants and personal fees from UCB, personal fees from BMS, grants and personal fees from Pfizer, grants and personal fees from MSD, personal fees from Novartis, personal fees from Gilead, personal fees from Lilly, outside the submitted work. Dr Gossec reports grants from Amgen, Lilly, Janssen, Pfizer, Sandoz, Sanofi, Galapagos, personal fees from AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, UCB, outside the submitted work. Dr Dougados reports grants from UCB, during the conduct of the study; grants and personal fees from AbbVie, grants and personal fees from Pfizer, grants and personal fees from Lilly, grants and personal fees from Novartis, grants and personal fees from Roche, grants and personal fees from BMS, grants and personal fees from Merck, outside the submitted work. Dr Dernis, Dr Ruyssen-Witrand, Dr Lenaerts, Dr Lopez-Medina, Dr Sparsa, Dr Starmans-Kool, Dr C Webers, Dr Pouplin, Dr Soubrier and Dr Joos have nothing to declare., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
16. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.
- Author
-
Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Brouwer E, Bos R, Lems WF, Colin EM, Allaart CF, Meek IL, Landewé R, Bernelot Moens HJ, van Riel PL, van de Laar MA, and Jansen TL
- Subjects
- Female, Humans, Male, Middle Aged, Remission Induction, Severity of Illness Index, Withholding Treatment, Arthritis, Rheumatoid drug therapy, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Objective: Tumor necrosis factor inhibitor (TNFi) biologic agents are an effective treatment for rheumatoid arthritis (RA). It is unclear whether patients whose disease is in remission or who have stable low disease activity need to continue use of TNFi or can stop this treatment. This study was undertaken to assess whether patients with established RA who are in remission or have stable low disease activity can effectively and safely stop their TNFi therapy., Methods: The study was designed as a pragmatic multicenter, open-label randomized controlled trial. Inclusion criteria were a diagnosis of RA according to the American College of Rheumatology 1987 classification criteria, as well as use of a TNFi for at least 1 year along with a stable dose of disease-modifying antirheumatic drugs and a Disease Activity Score in 28 joints (DAS28) of <3.2 over the 6 months preceding trial inclusion. Patients were randomized in a 2:1 ratio to either stop or continue treatment with their current TNFi. Flare was defined as a DAS28 of ≥3.2 during the 12-month follow-up period and an increase in score of ≥0.6 compared to the baseline DAS28., Results: In total, 531 patients were allocated to the stop group and 286 to the TNFi continuation group. At 12 months, more patients had experienced a flare in the stop group (272 [51.2%] of 531) than in the continuation group (52 [18.2%] of 286; P < 0.001). The hazard ratio for occurrence of a flare after stopping TNFi was 3.50 (95% confidence interval [95% CI] 2.60-4.72). The mean DAS28 in the stop group was significantly higher during the follow-up period compared to that in the continuation group (P < 0.001). Of the 195 patients who restarted TNFi treatment after experiencing a flare and within 26 weeks after stopping, 165 (84.6%) had regained a DAS28 of <3.2 by 6 months later, and the median time to a regained DAS28 of <3.2 was 12 weeks (95% Cl 10.7-13.3). There were more hospitalizations in the stop group than in the continuation group (6.4% versus 2.4%)., Conclusion: Stopping TNFi treatment results in substantially more flares than does continuation of TNFi in patients with established RA in remission or with stable low disease activity., (© 2016, American College of Rheumatology.)
- Published
- 2016
- Full Text
- View/download PDF
17. [Anakinra in refractory adult onset Still's disease].
- Author
-
Vercoutere W, Starmans-Kool M, and Peeters RM
- Subjects
- Female, Humans, Treatment Outcome, Young Adult, Antirheumatic Agents therapeutic use, Interleukin 1 Receptor Antagonist Protein therapeutic use, Receptors, Interleukin-1 antagonists & inhibitors, Still's Disease, Adult-Onset diagnosis, Still's Disease, Adult-Onset drug therapy
- Abstract
Background: Adult onset Still's disease (AOSD) is a rare--but potentially dangerous and difficult to treat--generalized auto-inflammatory disease which shares some similarities with the systemic form of juvenile idiopathic arthritis (SoJIA or Still's disease)., Case Description: AOSD was diagnosed in 2 young adult women of 21 and 23 years old. The disease was found to be resistant to treatment in these patients. The patients were treated successively with NSAIDs, glucocorticoids, methotrexate and anti tumour necrosis factor(TNF)-α antagonists, with only partial effects or none at all. Treatment with the interleukin-1 receptor antagonist anakinra was subsequently started, which led to remission of AOSD., Conclusion: These cases illustrate the clinical spectrum of AOSD and the possibility of an important addition to the therapeutic arsenal for treatment of refractory AOSD.
- Published
- 2011
18. [A rare cause of clubbing of fingers and watch glass nails].
- Author
-
Linssen-Ramakers DH, Starmans-Kool MJ, and Peeters HR
- Subjects
- Humans, Male, Middle Aged, Osteoarthropathy, Secondary Hypertrophic diagnostic imaging, Osteoarthropathy, Secondary Hypertrophic pathology, Prosthesis-Related Infections diagnostic imaging, Prosthesis-Related Infections surgery, Tomography, X-Ray Computed, Osteoarthropathy, Secondary Hypertrophic diagnosis, Osteoarthropathy, Secondary Hypertrophic etiology, Prosthesis-Related Infections complications
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.